FASN and cholangiocarcinoma: To evaluate the prognostic role of lipid-metabolizing enzyme expression in CCA patients, the Kaplan-Meier survival curves showed that CCA patients with high expression of FASN and HMGCR were associated with shorter overall survival times (p = 0.008 and p = 0.044, respectively) (Figure 1C).